Report Search Results (Showing 1 to 20 of 56)	As of 21-Nov-2009
New Screen

All Reports | Brokerage Reports | Independent Reports

Release Date  Contributor Author Title Pages Price StarMine Author Rating More Info EPS Accuracy * Portfolio Return ** 13-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Meetings with management: Putting the ship back on course 9 $25     View Abstract 13-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino LPATH Reports Strong Q3 6 $25     View Abstract 12-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino NRGX Q3 Earnings Close To Expectations, Looking To Clinical Data In H1 2010 6 $25     View Abstract 11-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Transition Q1 (FY2010) In-Line, First Half Of 2010 Will Be Transitional 5 $10     View Abstract 11-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Suspending coverage of Penwest 4 $10     View Abstract 10-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino INFI Beats Consensus Q309 EPS 6 $25     View Abstract 10-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Q3 results a non-event as 2010-11 launches the key 7 $25     View Abstract 9-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Focus all on 2010 post ~in-line Q3 7 $25     View Abstract 9-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Q2 In-Line: Vilazodone NDA Filing And Phase 3 Stedivaze Study Next Big Steps 9 $25     View Abstract 6-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino ALKS Quarter More Or Less In-Line: Things Get Interesting In 2010 8 $25     View Abstract 6-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino HALO Q3 As Expected 6 $25     View Abstract 6-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino NGSX Q3 In-Line, FDA Approval Expected To Bring The Heat In Q4 6 $25     View Abstract 6-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino OMPI Q3 Results In-Line, With A Stealth New Product Launch 7 $25     View Abstract 6-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Q3 In-Line; Zenpep Launch On Deck 7 $25     View Abstract 5-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino SNMX Q3 In-Line, Looking to Taste More Revenue in 2010 6 $25     View Abstract 5-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Q3 Earnings Call Ho Hum, Looking For BLA Resubmission In Q1 2010 6 $25     View Abstract 5-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Q3 Loss Greater Than Expected 7 $25     View Abstract 5-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino BUY Now In Advance Of Phase 3 Dimebon Data in H1 2010 8 $25     View Abstract 5-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Q3 beats on marginal quality 6 $25     View Abstract 5-Nov-09 Roth Capital Partners, Inc. Scott R. Henry CFA, Andrew Vaino Q3 fundamentals strong, but focus on patents and OTC decision 7 $25     View Abstract Next 20